Solicitation of Nominations for Appointment to the Healthcare Infection Control Practices Advisory Committee (HICPAC), 10440-10441 [2020-03585]
Download as PDF
<![CDATA[
10440
Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices
lotter on DSKBCFDHB2PROD with NOTICES
affected persons. The identification and
notification of those exposed is an
essential first step in providing the
exposed access to potentially life-saving
medical screening, follow-up, disease
prevention measures, including
vaccination and other preventive
treatments, and medical treatment and
supportive care. Preventing secondary
cases among contacts, in turn, helps
prevent the propagation and spread of
disease within the community.
Therefore, travelers and the public at
large derive direct benefit from a system
that ensures that, if an exposure has
occurred, health authorities can
identify, locate, and notify affected
passengers and those individuals who
came into contact with them within the
incubation period of the disease.
Contact tracing is effective at reducing
cases of communicable disease at the
early stages of a potential outbreak if the
contacts are notified as soon after initial
exposure as possible. If an efficient
contact system is not in place when the
first ill passengers arrive, the benefits of
the contact tracing are greatly
diminished.
Order of the Centers for Disease Control
and Prevention, Department of Health
and Human Services Under 42 CFR
71.31 and 71.4
Attn: Each airline carrying a
passenger who has departed from, or
was otherwise present within, the
People’s Republic of China (excluding
the special administrative regions of
Hong Kong and Macau) within 14 days
of the date of the passenger’s entry or
attempted entry into the United States
via that airline’s carriage.
In accordance with 42 CFR 71.31(b)
and 71.4(d), as authorized by 42 U.S.C.
264:
1. Each airline is hereby ordered to
collect and provide information about
any passenger who has departed from,
or was otherwise present within, the
People’s Republic of China (excluding
the special administrative regions of
Hong Kong and Macau) within 14 days
of the date of the passenger’s entry or
attempted entry into the United States
via that airline’s carriage (‘‘Designated
Passengers’’).
2. Each airline must collect and
provide the following information
(‘‘Designated Information’’) to the extent
such information exists for any
Designated Passenger carried by that
airline:
a. Full name (last, first, and, if
available, middle or others);
b. Primary contact phone number to
include country code, at which a
Designated Passenger can be contacted
while in the United States;
VerDate Sep<11>2014
18:30 Feb 21, 2020
Jkt 250001
c. Secondary contact phone number to
include country code;
d. Address or addresses while a
Designated Passenger is in the United
States (number and street, city, State,
and zip code), except that a U.S. citizen
or a lawful permanent resident will
provide address of permanent residence
in the United States (number and street,
city, State, and zip code); and
e. Email address that a Designated
Passenger will use for email
communications while in the United
States.
3. Each airline must produce, using
existing data-sharing channels, the
Designated Information to the Director
of the CDC’s Division of Global
Migration and Quarantine (‘‘DGMQ’’), or
his representative. If existing datasharing channels become unavailable,
within 12 hours, the affected airline or
airlines must identify an alternate
means of transmitting the required data
in a manner acceptable to CDC.
4. Each airline must provide
Designated Information within 2 hours
of the departure of the flight carrying a
Designated Passenger.
5. Before or immediately upon arrival
in the United States, each airline must
provide to CDC (the head of the arrival
airport’s Quarantine Station) the name
of any Designated Passenger who had
refused or was otherwise unable to
provide all five fields of the Designated
Information prior to departure.
6. Each airline must provide
Designated Information for the duration
of the January 31, 2020 Proclamation on
Suspension of Entry as Immigrants and
Nonimmigrants of Persons who Pose a
Risk of Transmitting 2019 Coronavirus.
This order will cease to be effective
when the Interim Final Rule at Federal
Register, Vol. 85, No. 29, ceases to be
effective.
The CDC Director has determined that
Designated Passengers may be at risk of
exposure to COVID–19. CDC will use
this information for the purposes of
public health follow-up, such as health
education, treatment, prophylaxis, or
other appropriate public health
interventions, including travel
restrictions.
‘‘Airline’’ as used in this order has the
meaning provided at 42 CFR 71.1(b).
Failure to comply with this order may
result in the imposition of fines or other
penalties as provided in 42 U.S.C. 271
and 42 CFR 71.2, or as otherwise
provided by law. CDC maintains
information retrieved by personal
identifier in accordance with federal
law, including the Privacy Act of 1974
(5 U.S.C. 552a). Identifiable information
may be shared only for lawful purposes,
including with authorized personnel of
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
the U.S. Department of Health and
Human Services, state and local public
health departments, and other
cooperating authorities. CDC will delete
the Designated Information when no
longer required for the purposes set
forth above, in accordance with federal
law, and request that State and local
governments do the same.
CDC may modify this order by an
updated publication in the Federal
Register or by posting an advisory to
follow at www.cdc.gov.
Paperwork Reduction Act
The Paperwork Reduction Act applies
to the collection of this information.
CDC has obtained approval from the
Office of Management and Budget
(OMB) for this data collection titled
‘Airline and Vessel and Traveler
Information Collection (42 CFR part 71)’
under OMB Control No. 0920–1180
(exp. May 30, 2020).
Dated: February 19, 2020.
Robert R. Redfield,
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2020–03636 Filed 2–19–20; 4:45 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Healthcare
Infection Control Practices Advisory
Committee (HICPAC)
ACTION:
Notice.
The Centers for Disease
Control and Prevention (CDC) is seeking
nominations for membership on the
HICPAC. The HICPAC consists of 14
experts in fields including but not
limited to, infectious diseases, infection
prevention, healthcare epidemiology,
nursing, clinical microbiology, surgery,
hospitalist medicine, internal medicine,
epidemiology, health policy, health
services research, public health, and
related medical fields. Nominations are
being sought for individuals who have
expertise and qualifications necessary to
contribute to the accomplishments of
the committee’s objectives. Nominees
will be selected based on expertise in
the fields of infectious diseases,
infection prevention, healthcare
epidemiology, nursing, environmental
and clinical microbiology, surgery,
internal medicine, and public health.
Federal employees will not be
considered for membership. Members
SUMMARY:
E:\FR\FM\24FEN1.SGM
24FEN1
lotter on DSKBCFDHB2PROD with NOTICES
Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices
may be invited to serve for four-year
terms.
Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of HICPAC
objectives https://www.cdc.gov/hicpac/.
DATES: Nominations for membership on
the HICPAC must be received no later
than August 3, 2020. Packages received
after this time will not be considered for
the current membership cycle.
ADDRESSES: All nominations should be
mailed to HICPAC, Division of
Healthcare Quality Promotion, NCEZID,
CDC, 1600 Clifton Road NE, Mailstop
H16–3, Atlanta, Georgia 30329–4027,
emailed (recommended) to hicpac@
cdc.gov, or faxed to (404) 639–4043.
FOR FURTHER INFORMATION CONTACT: KooWhang Chung, MPH, HICPAC, Division
of Healthcare Quality Promotion,
NCEZID, CDC, 1600 Clifton Road NE,
Mailstop H16–3, Atlanta, Georgia
30329–4027; hicpac@cdc.gov.
SUPPLEMENTARY INFORMATION: The U.S.
Department of Health and Human
Services policy stipulates that
committee membership be balanced in
terms of points of view represented, and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens,
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees (SGEs), requiring the filing
of financial disclosure reports at the
beginning and annually during their
terms. CDC reviews potential candidates
for HICPAC membership each year and
provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment near
the start of the term in July 2021, or as
soon as the HHS selection process is
completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year. SGE Nominees must be
U.S. citizens, and cannot be full-time
employees of the U.S. Government.
Candidates should submit the following
items:
D Current curriculum vitae, including
complete contact information
VerDate Sep<11>2014
18:30 Feb 21, 2020
Jkt 250001
(telephone numbers, mailing address,
email address).
D At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the
candidate him- or herself, or by the
person/organization recommending the
candidate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–03585 Filed 2–21–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Injury Prevention
and Control, (BSC, NCIPC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
National Center for Injury Prevention
and Control, (BSC, NCIPC). This
meeting is open to the public limited
only by the space and ports available.
There will be 2,000 telephone ports
available. There will be a public
comment period at the end of the
meeting; from 3:00 p.m.–3:45 p.m., EDT.
DATES: The meeting will be held on
April 30, 2020, 12:30 p.m. to 3:50 p.m.,
EDT.
ADDRESSES: Teleconference: Dial-In
Number: 1–800–369–3110, Participant
Code: 7563795.
FOR FURTHER INFORMATION CONTACT:
Gwendolyn H. Cattledge, Ph.D.,
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
10441
M.S.E.H., Deputy Associate Director for
Science, NCIPC, CDC, 4770 Buford
Highway NE, Mailstop F–63, Atlanta,
GA 30341, Telephone (770) 488–1430;
Email address: ncipcbsc@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board will: (1) Conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases, and other impairments; (2)
assist States and their political
subdivisions in preventing and
suppressing communicable and noncommunicable diseases and other
preventable conditions and in
promoting health and well-being; and
(3) conduct and assist in research and
control activities related to injury. The
Board of Scientific Counselors makes
recommendations regarding policies,
strategies, objectives, and priorities; and
reviews progress toward injury
prevention goals and provides evidence
in injury prevention-related research
and programs. The Board also provides
advice on the appropriate balance of
intramural and extramural research, the
structure, progress and performance of
intramural programs. The Board is
designed to provide guidance on
extramural scientific program matters,
including the: (1) Review of extramural
research concepts for funding
opportunity announcements; (2)
conduct of Secondary Peer Review of
extramural research grants, cooperative
agreements, and contracts applications
received in response to the funding
opportunity announcements as it relates
to the Center’s programmatic balance
and mission; (3) submission of
secondary review recommendations to
the Center Director of applications to be
considered for funding support; (4)
review of research portfolios; and (5)
review of program proposals.
Matters To Be Considered: The agenda
will discuss an update on the CDC
Opioid Prescribing Estimates Project,
the Management of Acute and Chronic
Pain: Opportunities for Stakeholder
Engagement, and Public Comments. In
addition, an update will be provided on
the formation of the BSC, NCIPC Opioid
Workgroup. Agenda items are subject to
change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 85, Number 36 (Monday, February 24, 2020)]
[Notices]
[Pages 10440-10441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03585]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the Healthcare
Infection Control Practices Advisory Committee (HICPAC)
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) is
seeking nominations for membership on the HICPAC. The HICPAC consists
of 14 experts in fields including but not limited to, infectious
diseases, infection prevention, healthcare epidemiology, nursing,
clinical microbiology, surgery, hospitalist medicine, internal
medicine, epidemiology, health policy, health services research, public
health, and related medical fields. Nominations are being sought for
individuals who have expertise and qualifications necessary to
contribute to the accomplishments of the committee's objectives.
Nominees will be selected based on expertise in the fields of
infectious diseases, infection prevention, healthcare epidemiology,
nursing, environmental and clinical microbiology, surgery, internal
medicine, and public health. Federal employees will not be considered
for membership. Members
[[Page 10441]]
may be invited to serve for four-year terms.
Selection of members is based on candidates' qualifications to
contribute to the accomplishment of HICPAC objectives https://www.cdc.gov/hicpac/.
DATES: Nominations for membership on the HICPAC must be received no
later than August 3, 2020. Packages received after this time will not
be considered for the current membership cycle.
ADDRESSES: All nominations should be mailed to HICPAC, Division of
Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE,
Mailstop H16-3, Atlanta, Georgia 30329-4027, emailed (recommended) to
[email protected], or faxed to (404) 639-4043.
FOR FURTHER INFORMATION CONTACT: Koo-Whang Chung, MPH, HICPAC, Division
of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE,
Mailstop H16-3, Atlanta, Georgia 30329-4027; [email protected].
SUPPLEMENTARY INFORMATION: The U.S. Department of Health and Human
Services policy stipulates that committee membership be balanced in
terms of points of view represented, and the committee's function.
Appointments shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, gender identity, HIV
status, disability, and cultural, religious, or socioeconomic status.
Nominees must be U.S. citizens, and cannot be full-time employees of
the U.S. Government. Current participation on federal workgroups or
prior experience serving on a federal advisory committee does not
disqualify a candidate; however, HHS policy is to avoid excessive
individual service on advisory committees and multiple committee
memberships. Committee members are Special Government Employees (SGEs),
requiring the filing of financial disclosure reports at the beginning
and annually during their terms. CDC reviews potential candidates for
HICPAC membership each year and provides a slate of nominees for
consideration to the Secretary of HHS for final selection. HHS notifies
selected candidates of their appointment near the start of the term in
July 2021, or as soon as the HHS selection process is completed. Note
that the need for different expertise varies from year to year and a
candidate who is not selected in one year may be reconsidered in a
subsequent year. SGE Nominees must be U.S. citizens, and cannot be
full-time employees of the U.S. Government. Candidates should submit
the following items:
[ssquf] Current curriculum vitae, including complete contact
information (telephone numbers, mailing address, email address).
[ssquf] At least one letter of recommendation from person(s) not
employed by the U.S. Department of Health and Human Services.
(Candidates may submit letter(s) from current HHS employees if they
wish, but at least one letter must be submitted by a person not
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the candidate him- or herself, or
by the person/organization recommending the candidate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-03585 Filed 2-21-20; 8:45 am]
BILLING CODE 4163-18-P
